| 词条 | ProQR |
| 释义 |
| name = ProQR | type = Public | traded_as = {{NASDAQ|PRQR}} | industry = Biotechnology Pharmaceuticals | founded = 2012 | hq_location_city = LEIDEN | key_people = Daniel de Boer (CEO) | products = Developing transformative RNA medicines | num_employees = {{Unbulleted list|150}} | num_employees_year = | website = http://www.proqr.com/ }}ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer,[1][2][3] Dinko Valerio[3][4] and Gerard Platenburg.[3][4] The company’s current pipeline includes RNA treatments for rare genetic diseases[5] including Leber's congenital amaurosis, (LCA10)[5][6] dystrophic epidermolysis bullosa[5][6] and Usher syndrome.[7] ProQR is targeting genetic diseases by focusing on making changes to the RNA[8]. ProQR’s RNA editing technology, called Axiomer[7], can make targeted single nucleotide changes to RNA. One of the company’s lead candidates[9], QR-110, is being developed to treat LCA10[10]. The drug will bind the mutated section of the RNA which will allow a formation of a normal CEP290 protein[11]. References1. ^{{cite news |last1=Weisman |first1=Robert |title=Henri Termeer isn’t exactly settling into retirement |url=https://www.bostonglobe.com/business/2013/01/20/genzyme-henri-termeer-isn-exactly-settling-into-retirement/XTZKFMGnP2AewNMVkk1gbJ/story.html |publisher=The Boston Globe |date=January 20, 2018}} {{netherlands-company-stub}}2. ^{{cite news |last1=McBride |first1=Ryan |title=Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups |url=https://www.fiercebiotech.com/r-d/henri-termeer-rediscovers-genzyme-feel-world-of-biotech-startups |publisher=FierceBiotech |date=May 10, 2013}} 3. ^1 2 {{cite news |last1=Carroll |first1=John |title=Termeer-backed ProQR lays out terms for $75M IPO |url=https://www.fiercebiotech.com/biotech/termeer-backed-proqr-lays-out-terms-for-75m-ipo |publisher=FierceBiotech |date=Sep 9, 2014}} 4. ^1 {{cite news |last1=Taylor |first1=Nick Paul |title=ProQR spins out CNS assets to form RNA rare disease biotech |url=https://www.fiercebiotech.com/biotech/proqr-spins-out-cns-assets-to-form-rna-rare-disease-biotech |publisher=FierceBiotech |date=Sep 13, 2017}} 5. ^1 2 {{cite news |last1=Rodríguez Fernández |first1=Clara |title=A Dutch Company on the Quest Against Cystic Fibrosis |url=https://labiotech.eu/proqr-cystic-fibrosis-daniel-de-boer/ |publisher=LaBiotech.eu |date=March 12, 2018}} 6. ^1 {{cite news |last1=Rossi |first1=Krista |title=Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB |url=http://www.raredr.com/news/daniel-de-boer-ceo-proqr-explains-rna-treatment-qr313-for-deb |publisher=Rare Disease Report |date=May 25, 2018}} 7. ^1 {{cite news |last1=Dale |first1=Alex |title=ProQR Tackles Blindness Caused by a Rare |url=https://labiotech.eu/blindness-deafness-usher-syndrome-proqr/ |publisher=LaBiotech.eu |date=Feb 13, 2018}} 8. ^{{Cite news|url=https://www.rdmag.com/article/2017/09/art-editing-rna|title=The Art of Editing RNA|date=2017-09-22|work=Research & Development|access-date=2018-10-04|language=en}} 9. ^{{Cite news|url=https://www.reuters.com/article/us-proqr-study/proqr-soars-as-childhood-blindness-drug-succeeds-in-early-trial-idUSKCN1LL0RN|title=ProQR soars as childhood blindness drug succeeds in early trial|last=Mathias|first=Tamara|work=U.S.|access-date=2018-10-04|language=en-US}} 10. ^{{Cite news|url=https://www.marketwatch.com/story/proqrs-stock-rockets-to-pace-all-gainers-after-upbeat-drug-trial-results-2018-09-05|title=ProQR's stock rockets to pace all gainers after upbeat drug trial results|last=Kilgore|first=Tomi|work=MarketWatch|access-date=2018-10-04|language=en-US}} 11. ^{{Cite web|url=http://www.evaluate.com/vantage/articles/news/trial-results/proqr-hits-gas-blindness-project|title=Proqr hits the gas on blindness project|website=Evaluate.com|language=en|access-date=2018-10-04}} 2 : Biotechnology companies of the Netherlands|Infobox drug templates |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。